Newron Pharmaceuticals Extends Loan Repayment with EIB

Newron Pharmaceuticals S.p.A. has reached an agreement with the European Investment Bank (EIB) to extend the repayment dates of its 2018 Finance Contract tranches to June 28, 2028. This move pertains to outstanding tranches under the existing financial arrangement. The amendments are subject to formalization through definitive agreements between the involved parties.

Roberto Galli, CFO of Newron, expressed gratitude for EIB's support in aligning loan obligations with the timeline of potential milestones associated with their lead drug candidate, evenamide. This compound is in phase III of the global ENIGMA-TRS program, targeting treatment-resistant schizophrenia.

The agreement's details can be found in Newron's 2024 Annual Report on their website. Newron continues to progress in developing therapies for central and peripheral nervous system diseases.